Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022.